Company intelligence / Profile preview
Lighthouse Pharmaceuticals
San Francisco, California, United Stateslighthousepharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
LHP588, their lead compound, has completed Phase 1 SAD/MAD studies demonstrating safety and tolerability with no serious adverse events. The FDA has cleared their IND application to proceed with the Phase 2 SPRING trial for P. gingivalis-positive Alzheimer's disease.
- Therapeutic areas
- CardiovascularOtherOncologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Quince Therapeutics (acquired protease inhibitor portfolio from them)
Beyond the preview
Go deeper on Lighthouse Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lighthouse Pharmaceuticals.